Dietrich John Pauls - Nov 16, 2022 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role
President and CEO, Director
Signature
/s/ Amy Culbert, attorney-in-fact
Stock symbol
DMAC
Transactions as of
Nov 16, 2022
Transactions value $
$24,200
Form type
4
Date filed
11/16/2022, 07:56 PM
Previous filing
Jun 2, 2022
Next filing
Jun 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DMAC Voting Common Shares, no par value per share Purchase $24.2K +20K +55.86% $1.21 55.8K Nov 16, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.17 to $1.21, inclusive. The reporting person undertakes to provide to DiaMedica Therapeutics Inc., any security holder of DiaMedica Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2 Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.